BLUE

bluebird bio, Inc. (BLUE) | Rumor.io

bluebird bio

BLUE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)96%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BLUE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Nov 17

$BLUE has seen significant price movements, with some users reporting gains of up to 5.5x.
Users are sharing their profit reports and calling out others who made successful trades on $BLUE.
The posts suggest that $BLUE was a popular and potentially volatile stock among traders.

Generated by AI

Sentiment

Of the messages about BLUE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.16% +28
Bearish	—	—	—	9.84% -28

Bullish· May 14

$BLUE's amended merger terms offer a 50% premium, with an upfront payment of $5 per share, representing a significant increase in value for shareholders.
The company's Q1 numbers show strong revenue growth, with $38 million in revenue, a 68% gross margin, and $78 million in cash, indicating a solid financial position and potential for future growth.
The acquisition offer by Carlyle represents a significant premium to the company's previous valuation, with some analysts suggesting that the company's value could reach $8 per share, indicating a strong bullish sentiment among investors.

Bearish· Feb 24

Poor management and mis-timed PR have contributed to the decline of $BLUE, leading to a loss for shareholders.
The company's sale of its gene therapies portfolio, including its FDA-approved drug for Sickle Cell, for less than $30M is a significant blow to investors.
The deal to sell the company for $3 per share is seen as a poor return for investors, with some predicting that the company's CVRs will be worth nothing, making the acquisition a $3 steal for the buyer.

Generated by AI

Topics

Of the messages about BLUE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	28.46%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	1.15%
Announcements	—	—	—	65.77%
Analysts	—	—	—	4.62%

Analysts· Jul 19

BofA Securities upgraded bluebird bio (BLUE) to a buy rating from neutral, citing the potential of sickle cell disease treatment lovo-cel, and raised the price target to $10 from $6.
Analysts project peak lovo-cel sales approaching $1 billion and the company becoming profitable in 2026, with the treatment's data being equal to or more robust than its closest competitor.
Barclays also upgraded shares of bluebird bio to an "overweight" rating, raising their target price for the stock to $8.00 from $7.00.

Announcements· May 14

Bluebird bio, Inc. ($BLUE) receives a higher upfront offer from private equity firms Carlyle Group and SK Capital Partners, valuing the company at $5 per share.
The amended merger agreement allows stockholders to elect between a cash payment with a contingent value right ($3.00 per share + $6.84) or a higher cash payment without it ($5.00 per share).
The expiration date of the tender offer has been extended to May 29, 2025, giving stockholders more time to make their election.

Technical Analysis· Dec 21

BLUE's oversold condition and potential for a rebound is discussed, with some analysts pointing to the stock's bottoming tail and strong dip-buying as signs of a possible turnaround.
The stock's recent price action, including a breakout above resistance and a rounding bottom on the cup and handle pattern, is seen as a bullish sign by some, with potential for a big breakout.
Analysts also point to the stock's oversold oscillators (MACD, STOCHASTIC, RSI) and the presence of a gap to be filled as additional evidence of a potential rebound, with some warning of a possible retrace before a larger move.

Generated by AI

Community

Of the messages about BLUE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	9.7%
Newcomers	—	—	100%	90.3%

Regulars· May 14

The amended merger terms offer bluebird bio, Inc. ($BLUE) shareholders a choice between $3.00 per share plus a contingent value right (CVR) of $6.84 per share or $5.00 per share with no CVR.
The tender deadline for the sweetened offer was May 12, suggesting that the original vote may not have been in favor of the company.
Bluebird bio, Inc.'s shares have moved 50.3% to $4.97, making it one of the top gainers in the market on Wednesday morning, May 14, 2025.

Newcomers· Nov 17

New users are calling for $BLUE to go viral, predicting a significant price increase.
Several newcomers are sharing their profit gains from calls on $BLUE, with some reporting returns of over 4x.
The users are discussing their calls on $BLUE, with some mentioning a CA (California) connection and others referring to a TG (Telegram) group.

Generated by AI

News

The Battle For Sickle Cell

2mo agoSeeking Alpha

Also Discussed

Investors talking about BLUE also mention

#	Name	Attention
1	TSVT - 2seventy bio, Inc.	——
2	Cellectis S.A. ADRCLLS	0%0
3	Agios Pharmaceuticals, Inc.AGIO	0%0
4	BioMarin Pharmaceutical IncBMRN	0%+0
5	BLCM - Bellicum Pharmaceuticals, Inc.	——
6	RDUS - Radius Recycling, Inc.	——
7	Ionis Pharmaceuticals, Inc.IONS	0%new
8	SGEN - Seagen Inc.	——
9	Alnylam Pharmaceuticals, Inc.ALNY	0%0
10	iShares Biotechnology ETFIBB	0.01%0

bluebird bio, Inc.

Location

Social

What share of all stock conversation is about BLUE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Nov 17

$BLUE has seen significant price movements, with some users reporting gains of up to 5.5x.
Users are sharing their profit reports and calling out others who made successful trades on $BLUE.
The posts suggest that $BLUE was a popular and potentially volatile stock among traders.

Generated by AI

Sentiment

Of the messages about BLUE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.16% +28
Bearish	—	—	—	9.84% -28

Bullish· May 14

$BLUE's amended merger terms offer a 50% premium, with an upfront payment of $5 per share, representing a significant increase in value for shareholders.
The company's Q1 numbers show strong revenue growth, with $38 million in revenue, a 68% gross margin, and $78 million in cash, indicating a solid financial position and potential for future growth.
The acquisition offer by Carlyle represents a significant premium to the company's previous valuation, with some analysts suggesting that the company's value could reach $8 per share, indicating a strong bullish sentiment among investors.

Bearish· Feb 24

Poor management and mis-timed PR have contributed to the decline of $BLUE, leading to a loss for shareholders.
The company's sale of its gene therapies portfolio, including its FDA-approved drug for Sickle Cell, for less than $30M is a significant blow to investors.
The deal to sell the company for $3 per share is seen as a poor return for investors, with some predicting that the company's CVRs will be worth nothing, making the acquisition a $3 steal for the buyer.

Generated by AI

Topics

Of the messages about BLUE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	28.46%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	1.15%
Announcements	—	—	—	65.77%
Analysts	—	—	—	4.62%

Analysts· Jul 19

BofA Securities upgraded bluebird bio (BLUE) to a buy rating from neutral, citing the potential of sickle cell disease treatment lovo-cel, and raised the price target to $10 from $6.
Analysts project peak lovo-cel sales approaching $1 billion and the company becoming profitable in 2026, with the treatment's data being equal to or more robust than its closest competitor.
Barclays also upgraded shares of bluebird bio to an "overweight" rating, raising their target price for the stock to $8.00 from $7.00.

Announcements· May 14

Bluebird bio, Inc. ($BLUE) receives a higher upfront offer from private equity firms Carlyle Group and SK Capital Partners, valuing the company at $5 per share.
The amended merger agreement allows stockholders to elect between a cash payment with a contingent value right ($3.00 per share + $6.84) or a higher cash payment without it ($5.00 per share).
The expiration date of the tender offer has been extended to May 29, 2025, giving stockholders more time to make their election.

Technical Analysis· Dec 21

BLUE's oversold condition and potential for a rebound is discussed, with some analysts pointing to the stock's bottoming tail and strong dip-buying as signs of a possible turnaround.
The stock's recent price action, including a breakout above resistance and a rounding bottom on the cup and handle pattern, is seen as a bullish sign by some, with potential for a big breakout.
Analysts also point to the stock's oversold oscillators (MACD, STOCHASTIC, RSI) and the presence of a gap to be filled as additional evidence of a potential rebound, with some warning of a possible retrace before a larger move.

Generated by AI

Community

Of the messages about BLUE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	9.7%
Newcomers	—	—	100%	90.3%

Regulars· May 14

The amended merger terms offer bluebird bio, Inc. ($BLUE) shareholders a choice between $3.00 per share plus a contingent value right (CVR) of $6.84 per share or $5.00 per share with no CVR.
The tender deadline for the sweetened offer was May 12, suggesting that the original vote may not have been in favor of the company.
Bluebird bio, Inc.'s shares have moved 50.3% to $4.97, making it one of the top gainers in the market on Wednesday morning, May 14, 2025.

Newcomers· Nov 17

New users are calling for $BLUE to go viral, predicting a significant price increase.
Several newcomers are sharing their profit gains from calls on $BLUE, with some reporting returns of over 4x.
The users are discussing their calls on $BLUE, with some mentioning a CA (California) connection and others referring to a TG (Telegram) group.

Generated by AI

bluebird bio

Social

Nov 17

Bullish· May 14

Bearish· Feb 24

Analysts· Jul 19

Announcements· May 14

Technical Analysis· Dec 21

Regulars· May 14

Newcomers· Nov 17

The Battle For Sickle Cell

Also Discussed

bluebird bio, Inc.

Company Information

Location

The Battle For Sickle Cell

Also Discussed

Social

Nov 17

Bullish· May 14

Bearish· Feb 24

Analysts· Jul 19

Announcements· May 14

Technical Analysis· Dec 21

Regulars· May 14

Newcomers· Nov 17